The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The Second Brazilian Early Lung Cancer Screening Trial (BRELT2)
Ricardo Sales Santos, MD, PhD, Hospital Israelita Albert Einstein, São Paulo, Brazil, provides an overview of the Second Brazilian Early Lung Cancer Screening Trial (BRELT2) in Brazil , carried out to validate the preliminary results of BRELT1. In this retrospective study, 3470 individuals who participated in lung cancer screening programs between December 2013 and January 2021 in six Brazilian institutions located in the states of São Paulo, Rio Grande do Sul, and Bahia were included. Diagnosis of lung cancer was observed in 74 patients (prevalence rate of 2.1%), with 52 (70.3%) in stage I or II. Lung cancer was diagnosed in 74 of 122 suspicious nodules (3.5% biopsy rate). Conclusively, lung cancer screening was feasible in all regional scenarios, despite the multitude of challenges for lung cancer screening in Brazil. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
